{"id":62024,"date":"2025-10-15T10:04:56","date_gmt":"2025-10-15T08:04:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/indivi-and-clouds-of-care-partner-to-advance-deep-phenotyping-in-early-alzheimers-and-parkinsons-drug-development\/"},"modified":"2025-10-15T10:04:56","modified_gmt":"2025-10-15T08:04:56","slug":"indivi-and-clouds-of-care-partner-to-advance-deep-phenotyping-in-early-alzheimers-and-parkinsons-drug-development","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/indivi-and-clouds-of-care-partner-to-advance-deep-phenotyping-in-early-alzheimers-and-parkinsons-drug-development\/","title":{"rendered":"Indivi and Clouds of Care Partner to Advance Deep Phenotyping in Early Alzheimer\u2019s and Parkinson\u2019s Drug Development"},"content":{"rendered":"
\n

BASEL, Switzerland–(BUSINESS WIRE)–Indivi and Clouds of Care, two independent TechBio companies, today announced a strategic partnership to advance the use of precision medicine tools in early-phase neuroscience drug development, targeting Alzheimer\u2019s and Parkinson\u2019s disease.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe field of neurodegeneration remains one of the toughest challenges in medicine, with a historically low probability of technical and regulatory success (PTRS). The highest attrition occurs between First-in-Human and Proof-of-Concept studies, where conventional endpoints lack the sensitivity needed to detect early treatment effects.<\/p>\n

\n\u201cAge being the principal risk factor for neurodegenerative diseases, we are facing a global pandemic<\/i>,\u201d says Michel Vounatsos, Chair of the Board of Directors of Clouds of Care. <\/b>\u201cDeep phenotyping technologies will be essential to improve drug development success in Alzheimer\u2019s and Parkinson\u2019s Disease and extend healthy brain ageing across the lifespan<\/i>.\u201d<\/p>\n

\nThe partnership will integrate world-class expertise in neuro-electrophysiology (resting-state EEG, event-related potentials, and polysomnography) with digital health technology tools. Together, they aim to establish a unified R&D framework for multimodal deep phenotyping, combining biological (electrophysiology-based) and functional (cognitive and motor behavior) measures to deliver earlier, more definitive Proof-of-Biology (PoB) and Proof-of-Concept (PoC) signals in early drug development trials.<\/p>\n

\nThis collaboration creates a technology-integrated value proposition, which de-risks early clinical development, by increasing the signal-to-noise ratio of PoB-PoC endpoints, thereby enhancing the PTRS, and potentially improving the risk-adjusted Net Present Value (rNPV) and accelerating time-to-market for biopharmaceutical partners.<\/p>\n

\nThe initiative aligns with the European Medicines Agency\u2019s (EMA) recent call for updated guidelines on early Alzheimer\u2019s trials, emphasizing the need for more responsive and clinically meaningful endpoints in early clinical phases.<\/p>\n

\n\u201cIt is not just about bringing deep phenotyping technologies together<\/i>,\u201d says Shibeshih Mitiku Belachew, Chief Medical Officer of Indivi. <\/b>\u201cIt is about creating a true symbiosis between clinical development and the science of enabling technologies to design smarter, faster, and more successful trials<\/i>.\u201d<\/p>\n

\nAbout <\/b>Indivi<\/b><\/a> <\/b>& Deep Phenotyping Measures of Cognitive and Motor Functions for Proof-of-Concept Demonstration of Disease Modification:<\/i><\/p>\n

\nIndivi is an ISO 13485 and ISO 27001-certified TechBio company headquartered in Basel (CH) and developing future-proof functional biomarkers derived from Digital Health Technology (DHT) tools measuring key disability concepts of importance (motion and cognition) for drug development trials in neuroscience.<\/p>\n